Custom-Made DNA vaccine takes on advanced liver cancer
NCT ID NCT04251117
First seen Apr 29, 2026 · Last updated May 02, 2026 · Updated 1 time
Summary
This study tests a personalized DNA vaccine (GNOS-PV02) plus an immune booster (INO-9012) combined with the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC), a type of liver cancer. The vaccine is custom-made for each patient based on their tumor's unique genetic markers. The goal is to see if the combination is safe and can help the immune system fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland Clinical Studies
Auckland, New Zealand
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.